Efficacy and Safety of Sodium Zirconium Cyclosilicate for Early Hyperkalemia After Kidney Transplantation
OBJECTIVE To evaluate the efficacy and safety of sodium zirconium cyclosilicate for early hyperkalemia after kidney transplantation.METHODS The cases of early hyperkalemia after renal transplantation treated with sodium zirconium silicate from September 2020 to January 2022 were retrospectively analyzed.They were divided into total group,single sodium zirconium silicate group and sodium zirconium silicate combined with insulin group.The demographic characteristics and basic clinical information of each group were compared,and the changes of serum potassium level,the range of potassium reduction and the standard-reaching rate before and after treatment were evaluated.RESULTS Before medication,the average serum potassium level of the 33 patients in total group was(6.05±0.48)mmol·L-1,and the average decreases of potassium at 24,48,72 h after medication were 1.10,1.03,1.15 mmol·L-1,with the standard-reaching rate of 78.10％,63.30％and 85.00％,respectively.Before medication,the average blood potassium level of sodium zirconate cyclosilicate group was(5.74±0.41)mmol·L-1,and the average potassium reduction range was 0.91,0.90,1.03 mmol·L-1 after treatment at 24,48,72 h,and the standard-reaching rate was 92.30％,80.00％and 100.00％,respectively.In the combined insulin group,the serum potassium level before medication was(6.25±0.41)mmol·L-1,and the average decreases of potassium at 24,48,72 h after medication was 1.24,1.10,1.24 mmol·L-1,and the standard-reaching rate was 68.40％,55.00％and 72.70％,respectively.In terms of safety,only 5 patients developed hypokalemia related to sodium zirconium cyclosilicate,and 1 patient developed constipation.CONCLUSION Sodium zirconium cyclosilicate can quickly reduce hyperkalemia in kidney transplant patients,but should be aware of hypokalemia.
万方数据
维普
